Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Arrowhead Pharmaceuticals is a clinical-stage RNAi therapeutics company developing targeted gene-silencing medicines using its proprietary TRiM platform. The company has multiple programs in Phase 2/3 trials targeting cardiometabolic diseases (plozasiran for hypertriglyceridemia, zodasiran for angiopoietin-like 3), rare diseases, and oncology, with recent partnership revenue driving the dramatic YoY growth. The stock trades on clinical trial readouts, regulatory milestones, and partnership deal announcements rather than traditional earnings metrics.
Arrowhead generates revenue through upfront payments, research funding, and milestone payments from pharmaceutical partners who license its RNAi platform and drug candidates. The 97.1% gross margin reflects the high-margin nature of licensing intellectual property and research services with minimal COGS. Long-term value creation depends on advancing pipeline candidates through clinical trials to commercialization, where the company would receive royalties (typically 10-20% of net sales) or retain commercial rights in certain markets. The TRiM platform's ability to deliver siRNA to extrahepatic tissues provides differentiation versus competitors limited to liver-targeted therapies.
Phase 2/3 clinical trial data readouts for lead programs plozasiran (cardiovascular outcomes) and zodasiran (ANGPTL3 inhibition)
FDA regulatory milestone achievements including IND clearances, Fast Track designations, and Breakthrough Therapy designations
New pharmaceutical partnership announcements with upfront payments and milestone structures
Competitive developments in RNAi therapeutics space from Alnylam, Ionis, and emerging gene therapy companies
Patent portfolio expansion and intellectual property protection for TRiM delivery platform
Clinical trial failure risk across multiple Phase 2/3 programs, with binary outcomes that could eliminate years of R&D investment and partnership value
Regulatory pathway uncertainty for novel RNAi modalities, particularly for extrahepatic delivery where long-term safety data is limited
Competitive pressure from established RNAi players (Alnylam with 5 approved products) and alternative modalities (antisense oligonucleotides, gene editing) targeting similar indications
Patent expiration and intellectual property challenges to TRiM platform, with potential for design-around strategies by competitors
Alnylam's dominant market position in RNAi with established commercial infrastructure and broader pipeline could limit partnership opportunities
Emerging gene editing technologies (CRISPR-based therapies) offering potential one-time cures versus chronic dosing may shift pharma partner interest
Large pharmaceutical companies developing internal RNAi capabilities reducing demand for platform partnerships
Future capital requirements to fund Phase 3 trials and commercial manufacturing may require dilutive equity raises if partnership revenue insufficient
Concentration risk in partnership revenue with potential for deal terminations or milestone payment delays affecting cash flow
Burn rate acceleration risk as multiple programs advance to later-stage trials requiring larger patient populations and longer duration studies
low - Clinical-stage biotech revenue is driven by partnership deal structures and trial milestones rather than economic cycles. However, broader risk appetite affects biotech valuations significantly, with growth stocks experiencing multiple compression during economic uncertainty. Partnership activity from large pharma can slow during recessions as acquirers become more conservative with capital deployment.
Rising interest rates negatively impact valuation through two mechanisms: (1) higher discount rates applied to distant future cash flows from products 3-7 years from commercialization compress present value, and (2) reduced risk appetite shifts capital away from speculative growth stocks toward income-generating assets. The company's $0.2B cash generation provides some buffer, but the 3.38x current ratio suggests reliance on capital markets for future funding needs. Rate increases also raise the opportunity cost of holding pre-revenue biotech versus yielding alternatives.
Minimal direct credit exposure given the company's strong balance sheet (0.55 debt/equity, 3.38x current ratio) and positive operating cash flow. However, credit market conditions affect ability to raise capital through convertible debt offerings, which are common financing vehicles for clinical-stage biotech. Tightening credit conditions can also impact pharmaceutical partners' willingness to commit large upfront payments in licensing deals.
growth - The 205% one-year return and 224% six-month return reflect momentum-driven speculation on clinical catalysts. Investors are primarily growth-focused biotech specialists willing to accept binary risk/reward profiles tied to trial outcomes. The negative net margin and pre-commercial status eliminate value and dividend investors. The recent 65% three-month surge suggests catalyst-driven trading around expected trial readouts rather than fundamental earnings growth.
high - Clinical-stage biotech exhibits extreme volatility around binary events (trial readouts, FDA decisions) with potential for 30-50% single-day moves. The stock's 224% six-month return demonstrates momentum characteristics. Beta likely exceeds 1.5x relative to broader market given the speculative nature and lack of earnings stability. Institutional ownership concentrated among specialized healthcare funds amplifies volatility during risk-off periods.
